1-<2-(dimethylamino)ethyl>-2,3(1H,4H)-quinoxalinedione | 76052-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-<2-(dimethylamino)ethyl>-2,3(1H,4H)-quinoxalinedione
• 英文别名: 1-(2-dimethylamino-ethyl)-1,4-dihydro-quinoxaline-2,3-dione；1-[2-(dimethylamino)ethyl]-2,3(1H,4H)-quinoxalinedione；4-[2-(dimethylamino)ethyl]-1H-quinoxaline-2,3-dione
• CAS: 76052-80-7
• 化学式: C₁₂H₁₅N₃O₂
• 分子量: 233.27
• InChiKey: XJDJTXJTSWRUFW-UHFFFAOYSA-N

物化性质

• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-<2-(dimethylamino)ethyl>-2,3(1H,4H)-quinoxalinedione 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-Chloro-1-[2-(dimethylamino)ethyl]quinoxalin-2-one
  参考文献：
  名称：

  Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

  摘要：

  A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound I was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.021
• 作为产物：
  描述：

  N-(2-二甲基氨基)乙基-2-硝基苯胺 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 1-<2-(dimethylamino)ethyl>-2,3(1H,4H)-quinoxalinedione
  参考文献：
  名称：

  Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

  摘要：

  A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound I was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.021

文献信息

• Quinoxalinones
  申请人：Beavers Pat Mary

  公开号：US20050148586A1

  公开（公告）日：2005-07-07

  The invention features quinoxalinones, pharmaceutical compositions containing them and methods of using them to treat, for example, diabetes.

  这项发明涉及喹喔啉酮，包含它们的药物组合物以及使用它们治疗糖尿病等疾病的方法。
• Piperazinylquinoxalines with central serotoninmimetic activity
  作者：William C. Lumma、Richard D. Hartman、Walfred S. Saari、Edward L. Engelhardt、Victor J. Lotti、Clement A. Stone

  DOI：10.1021/jm00133a019

  日期：1981.1

  Regioselective syntheses of substituted 2-chloroquinoxalines and derived 2-(1-piperazinyl)quinoxalines are described. Selectivity in regards to serotonin reuptake blocking and serotoninmimetic activities of the piperazinylquinoxalines is reported. In general, introduction of a 6-substituent into the piperazinylquinoxaline enhanced serotonin reuptake blocking activity and diminished serotoninmimetic activity. Unsubstituted and 3-hydroxypiperazinylquinoxalines had primarily serotoninmimetic activity.
• LUMMA W. C. JR.; HARTMAN R. D.; SAARI W. S.; ENGELHARDT E. L.; LOTTI V. J+, J. MED. CHEM., 1981, 24, NO 1, 93-101
  作者：LUMMA W. C. JR.、 HARTMAN R. D.、 SAARI W. S.、 ENGELHARDT E. L.、 LOTTI V. J+

  DOI：——

  日期：——
• (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1711184B1

  公开（公告）日：2007-07-18
• Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors
  作者：Joseph Dudash、Yongzheng Zhang、John B. Moore、Richard Look、Yin Liang、Mary Pat Beavers、Bruce R. Conway、Philip J. Rybczynski、Keith T. Demarest

  DOI：10.1016/j.bmcl.2005.07.021

  日期：2005.11

  A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound I was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound. (c) 2005 Elsevier Ltd. All rights reserved.